PPI adverse drugs reactions: a retrospective study.
Adverse reaction
Allergy
Hypersensitivity
PPI
Proton pump inhibitors
Journal
Clinical and molecular allergy : CMA
ISSN: 1476-7961
Titre abrégé: Clin Mol Allergy
Pays: England
ID NLM: 101152195
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
06
2018
accepted:
10
01
2019
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
25
1
2019
Statut:
epublish
Résumé
Proton pump inhibitors (PPIs) are drugs capable of blocking the gastric pump H,K-ATPase in order to inhibit gastric acid secretion. Omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole belong to PPIs category. Although PPIs have a good safety profile, allergic reactions to these molecules can occur. The real rate of hypersensitive reactions to PPIs is unknown. The aim of this retrospective study is to evaluate the rate of hypersensitive reactions to PPIs in patients admitted to our Unit between 2008 and 2013 with a history of drug hypersensitivity. From a database of 1229 patients (921 women, 308 men) with adverse drug reaction we extrapolated the data about PPI reactions. Twelve patients (10 female, 2 men) had a positive history for hypersensitive reaction to PPI. Pantoprazole was the most frequently PPI involved. Based on patient personal history in some cases we performed an oral challenge test for an alternative anti-acid drug and none of them had adverse reactions. According to our experience and according to the literature and pharmacovigilance reports, ADR caused by PPIs are ever increasing. Adverse reactions to these drugs are still under-reported; however, considering the frequency of their prescription worldwide, the risk of severe allergic events is low. Further studies are needed to provide clearer data on the real incidence and prevalence about this matter. This should be useful to help physician in choosing the molecule to prescribe and, in case of hypersensitivity, the alternative molecule to test, also considering the possible cross-reactivity.
Identifiants
pubmed: 30675130
doi: 10.1186/s12948-019-0104-4
pii: 104
pmc: PMC6337765
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1Références
Allergol Immunopathol (Madr). 2002 Nov-Dec;30(6):342-3
pubmed: 12464168
Drugs. 2003;63(24):2739-54
pubmed: 14664653
J Allergy Clin Immunol. 2006 Mar;117(3):707-8
pubmed: 16522476
J Investig Allergol Clin Immunol. 2006;16(3):203-9
pubmed: 16784015
J Investig Allergol Clin Immunol. 2008;18(2):140-1
pubmed: 18447149
Allergy. 2008 Sep;63(9):1251-2
pubmed: 18699945
Curr Gastroenterol Rep. 2008 Dec;10(6):528-34
pubmed: 19006606
J Investig Allergol Clin Immunol. 2009;19(1):57-60
pubmed: 19274931
J Investig Allergol Clin Immunol. 2010;20(2):157-61
pubmed: 20461971
World J Gastroenterol. 2010 May 21;16(19):2323-30
pubmed: 20480516
Allergol Immunopathol (Madr). 2011 Jan-Feb;39(1):54
pubmed: 20678852
J Investig Allergol Clin Immunol. 2010;20(4):360-1
pubmed: 20815321
Allergol Immunopathol (Madr). 2012 Nov-Dec;40(6):393-4
pubmed: 22115571
Curr Opin Allergy Clin Immunol. 2012 Aug;12(4):348-53
pubmed: 22744268
Acta Clin Belg. 2012 Jul-Aug;67(4):301-3
pubmed: 23019809
J Drugs Dermatol. 2012 Oct;11(10):e43-7
pubmed: 23134998
Clin Exp Allergy. 2013 Mar;43(3):344-52
pubmed: 23414543
J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):589-94
pubmed: 23830408
Ann Allergy Asthma Immunol. 2013 Dec;111(6):452-7
pubmed: 24267357
Eur J Dermatol. 2014 May-Jun;24(3):413-5
pubmed: 24751668
J Investig Allergol Clin Immunol. 2014;24(2):130-2
pubmed: 24834779
Contact Dermatitis. 2014 Dec;71(6):377-8
pubmed: 25377305
Gastroenterol Hepatol. 2017 Jan;40(1):20-21
pubmed: 26794837
Curr Allergy Asthma Rep. 2016 Mar;16(3):17
pubmed: 26810177
J Gastroenterol. 2016 Aug;51(8):751-67
pubmed: 27325300
Int Arch Allergy Immunol. 2016;171(1):54-60
pubmed: 27838693